IGM Bio­sciences banks a $103M megaround on its quest to pi­o­neer a new kind of can­cer-fight­ing an­ti­body

A low-pro­file biotech out to shake up how the in­dus­try imag­ines an­ti­body ther­a­peu­tics is at­tract­ing some eye­balls to­day with a $103 mil­lion megaround.

IGM Bio­sciences is still shy­ing away from the lime­light, on­ly di­vulging in a three-para­graph state­ment that its lead pro­gram, a CD20xCD3 bis­pe­cif­ic, is ex­pect­ed to en­ter the clin­ic lat­er this year for re­lapsed/re­frac­to­ry B cell non-Hodgkin’s lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.